<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01861626</url>
  </required_header>
  <id_info>
    <org_study_id>V00057 CA 1 01</org_study_id>
    <secondary_id>2013-000988-80</secondary_id>
    <nct_id>NCT01861626</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of V0057 Versus a Reference Formulation After Single Administration in Healthy Male Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Dermatology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Dermatology</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the bioequivalence (comparison of the rate and
      extent of the active substance into the body following single administration of the drugs)
      between the test product V0057 and a reference product after two single oral administration
      separate by 7 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>18 time points up to 72h after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Concentration (Tmax)</measure>
    <time_frame>18 time points up to 72h after administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under curve (AUC0-72)</measure>
    <time_frame>18 time points up to 72h after administration</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>sequence 1 : Test drug - Reference</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2 : Reference - Test drug</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>V0057 - A mg</intervention_name>
    <description>Single oral administration</description>
    <arm_group_label>sequence 1 : Test drug - Reference</arm_group_label>
    <arm_group_label>Sequence 2 : Reference - Test drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <description>Single oral administration</description>
    <arm_group_label>sequence 1 : Test drug - Reference</arm_group_label>
    <arm_group_label>Sequence 2 : Reference - Test drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subject aged 18 to 50 years (inclusive)

        Exclusion Criteria:

          -  Presence of any significant medical finding or significant history that may impact the
             safety, the interpretation of the results and/or the participation of the subject in
             the study according to the opinion of the investigator

          -  Presence of any clinically significant abnormal finding at examination in the
             Investigator's opinion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Erfurt</city>
        <zip>D-99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2013</study_first_submitted>
  <study_first_submitted_qc>May 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2013</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

